Table 1.
Clinical and metadata of breakthrough infection cases and control groups.
| Positives after full vaccination |
Positives after full vaccination (viral load below the limit of detection or false positives) |
Control group 1 (ELISA, Ct, and cell culture) |
Control group 2 (whole genome sequencing) |
|
|---|---|---|---|---|
| Total number of patients | 109 | 24 | 124 | 335 |
| Median age in years (range) | 51 (23 - >90) | 52 (23 - 79) | 36 (0 - >90) | 40 (0 - >90) |
| >65 | 30 | 4 | 10 | 47 |
| 50-64 | 26 | 12 | 27 | 74 |
| 18-49 | 53 | 8 | 61 | 147 |
| <18 | 0 | 0 | 26 | 67 |
| Collection months | ||||
| Dec-20 | 0 | 0 | 2 (1.6) | 0 |
| Jan-21 | 2 (1.8) | 2 (8.3) | 17 (13.7) | 5 (1.5) |
| Feb-21 | 7 (6.4) | 3 (12.5) | 79 (63.7) | 5 (1.5) |
| Mar-21 | 16 (14.7) | 7 (29.2) | 26 (21) | 50 (14.9) |
| Apr-21 | 73 (67) | 9 (37.5) | 0 | 245 (73.1) |
| May-21 | 12 (11) | 2 (8.3) | 0 | 30 (9) |
| No. (%) of | ||||
| Male | 40 (36.7) | 6 (25) | 52 (41.9) | 151 (45.1) |
| Female | 69 (63.3) | 18 (75) | 72 (58.1) | 184 (54.9) |
| Symptomatic | 68 (62.4) | 8 (28.6) | 111 (89.5) | 291 (86.9) |
| Asymptomatic | 41 (37.6) | 16 (66.6) | 13 (10.5) | 44 (13.1) |
| Severity (%) | ||||
| Outpatient | 98 (89.9) | 24 (100) | 118 (95.2) | 269 (80.3) |
| Hospitalized for COVID-19 | 11 (10.1) | 0 | 6 (4.8) | 66 (19.7) |
| ICU admission | 2 (1.8) | 0 | 3 (2.4) | 23 (6.9) |
| Comorbidities (%) | ||||
| Hypertension | 49 (44.9) | 10 (41.7) | 42 (33.8) | 112 (33.4) |
| Respiratory Failure | 16 (14.7) | 0 | 9 (7.3) | 56 (16.7) |
| Pregnancy | 8 (7.3) | 2 (8.3) | 9 (7.3) | 18 (5.4) |
| Lung Disease | 29 (26.6) | 5 (20.8) | 31 (25) | 61 (18.2) |
| Kidney Disease | 26 (23.8) | 3 (12.5) | 17 (13.7) | 52 (15.5) |
| Immunosuppression | 29 (26.6) | 5 (20.8) | 27 (21.8) | 58 (17.3) |
| Diabetes | 26 (23.8) | 3 (12.5) | 14 (11.3) | 67 (20) |
| Heart Failure | 23 (21.1) | 3 (12.5) | 9 (7.3) | 31 (9.3) |
| Atrial Fibrillation | 12 (11) | 0 | 5 (4) | 22 (6.6) |
| Smoker | 9 (8.3) | 3 (12.5) | 21 (16.9) | 48 (14.3) |
| Cerebrovascular Disease | 6 (5.5) | 1 (4.2) | 7 (5.6) | 18 (5.4) |
| Cancer | 54 (49.5) | 10 (41.7) | 32 (25.8) | 56 (16.7) |
| Coronary Artery Disease | 29 (26.6) | 6 (25) | 20 (16.1) | 67 (20) |
| Patients with no/ unknown comorbidities | 28 (25.7) | 7 (29.2) | 42 (33.9) | 132 (39.4) |
| Patients with one comorbidity | 19 (17.4) | 6 (25) | 29 (23.4) | 66 (19.7) |
| Patients with two or more comorbidities | 62 (56.9) | 11 (45.8) | 53 (42.7) | 137 (40.9) |
| Median days after COVID-19 vaccine (range) | 52 (2 - 99) | 19.5 (3 - 100) | ||